MCID: DYS015
MIFTS: 50

Dysentery

Categories: Blood diseases, Gastrointestinal diseases

Aliases & Classifications for Dysentery

MalaCards integrated aliases for Dysentery:

Name: Dysentery 12 44 15 17 71
Infectious Diarrhea 12 54 62

Classifications:



External Ids:

Disease Ontology 12 DOID:12384
ICD9CM 34 009.2
MeSH 44 D004403
SNOMED-CT 67 154268000
UMLS 71 C0013369

Summaries for Dysentery

PubMed Health : 62 About infectious diarrhea: Diarrhea is very common: In Germany, for instance, adults get it once a year on average, and it is even more common in children. It is usually caused by viruses, the most common of which are the highly contagious norovirus and rotavirus. Infectious diarrhea can also come from bacteria such as Salmonella or Campylobacter. In normal cases of diarrhea, you can usually just replace the fluids you lose and wait until the infection goes away. But more severe or longer lasting diarrhea needs to be treated because it can lead to the loss of dangerously high levels of fluid and salt, especially in young children and older people.

MalaCards based summary : Dysentery, also known as infectious diarrhea, is related to amebiasis and shigellosis, and has symptoms including diarrhea An important gene associated with Dysentery is ALB (Albumin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Loperamide and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and skin.

Disease Ontology : 12 An intestinal infectious disease that involves inflammation of the intestines, especially colon, due to chemical irritants, bacteria, protozoa, or parasitic worms, which results in severe diarrhea with passage of mucus and blood.

Wikipedia : 74 Dysentery is a type of gastroenteritis that results in diarrhea with blood. Other symptoms may include... more...

Related Diseases for Dysentery

Diseases related to Dysentery via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 804)
# Related Disease Score Top Affiliating Genes
1 amebiasis 32.5 TNF IL1B CXCL8 ALB
2 shigellosis 32.2 TNF IL1B CXCL8 ALB
3 diarrhea 31.2 TTR TNF IL6 IL1B IFNA2 CXCL8
4 typhoid fever 31.0 TNF IL6 IL1B IL1A CRP CCR6
5 colitis 30.9 TNF IL6 IL1B CXCL8 CCR6
6 keratoconjunctivitis 30.9 TNF IL6 CXCL8 ALB
7 enterocolitis 30.8 TNF IL6 CXCL8 CRP
8 salmonellosis 30.7 TNF IL6 IL1B CXCL8 CCR6 ALB
9 ulcerative colitis 30.6 TNF IL6 IL1B CXCL8 CRP CCR6
10 ascaris lumbricoides infection 30.6 IL6 IL1B CXCL8
11 scarlet fever 30.6 TNF CRP ALB
12 acute diarrhea 30.5 STX2 STX1A ST8SIA2
13 lactose intolerance 30.5 CRP ATP12A ALB
14 syphilis 30.5 CRP CCR6 ALB
15 gastroenteritis 30.4 TNF IL6 IL1B IFNA2 CXCL8 CRP
16 sleeping sickness 30.4 TF IL6 HP H2AC18
17 intussusception 30.4 IL6 CRP ALB
18 tetanus 30.4 TNF IL6 IL1B IL1A CRP ALB
19 irritable bowel syndrome 30.3 TNF IL6 IL1B CXCL8 CRP
20 conjunctivitis 30.3 TNF IL6 CXCL8
21 disseminated intravascular coagulation 30.3 TNF IL6 CRP
22 disease by infectious agent 30.3 TNF IL6 IL1B HP H2AC18 CRP
23 guillain-barre syndrome 30.3 TNF HP ALB
24 paratyphoid fever 30.3 TNF IL1B IL1A CRP CCR6
25 appendicitis 30.3 TNF IL6 IL1B ENO2 CXCL8 CRP
26 viral hepatitis 30.2 TNF IL6 IL1B IFNA2 CRP ALB
27 toxic megacolon 30.2 TNF CRP CCR6 ATP12A ALB
28 gastritis 30.2 TNF IL6 IL1B CXCL8 CCR6
29 abdominal tuberculosis 30.2 TNF CRP ALB
30 spondylosis 30.2 IL1B ENO2 CRP
31 plague 30.2 TNF IL6 IL1B H2AC18 ALB
32 peritonitis 30.2 TNF IL6 IL1B CXCL8 CRP ALB
33 enthesopathy 30.2 TNF CRP CCR6
34 drug allergy 30.2 CRP ATP12A ALB
35 autonomic nervous system disease 30.1 TTR IL6 ALB
36 brucellosis 30.1 TNF IL6 CXCL8 CRP
37 uremia 30.1 TNF IL6 CRP ALB
38 meningitis 30.1 TNF IL6 IL1B IL1A CXCL8 CRP
39 pleural empyema 30.1 IL6 ENO2 CRP ALB
40 toxic shock syndrome 30.1 TNF IL6 IL1B CXCL8 CRP
41 allergic disease 30.1 TNF IL6 IL1B CCR6
42 cystitis 30.1 TNF IL6 IL1A CXCL8 CRP
43 graft-versus-host disease 30.0 TNF IL6 IL1B IL1A
44 duodenal ulcer 30.0 TNF IL6 IL1B CXCL8
45 infective endocarditis 30.0 TNF IL6 CRP
46 pasteurellosis 30.0 TNF HP CXCL8 ALB
47 iron deficiency anemia 30.0 TNF TF IL6 CRP
48 opisthorchiasis 30.0 TNF IL1B CXCL8
49 brain edema 30.0 IL6 IL1B CRP ALB
50 hepatitis a 30.0 TNF IL1B IFNA2 ALB

Comorbidity relations with Dysentery via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Dysentery:



Diseases related to Dysentery

Symptoms & Phenotypes for Dysentery

UMLS symptoms related to Dysentery:


diarrhea

Drugs & Therapeutics for Dysentery

PubMed Health treatment related to Dysentery: 62

You lose fluids and electrolytes when you have diarrhea , so it is important to replace them. For acute , non-severe diarrhea you usually just need something like tea with sugar and some salted crackers. Foods that are gentle on the stomach is recommended too, such as rice, bananas or rusk bread. Some people also avoid coffee, fruit juices, sodas, alcohol and fatty foods to keep from irritating their bowel even more. Acute , non-severe diarrhea does not require special treatment in adults and teenagers. But it is a good idea for young children and older people, as well as people with more severe diarrhea, to replace fluids and electrolytes by using oral rehydration salts (electrolyte /glucose solutions) from the pharmacy. These are powders containing salts, minerals and glucose that can be dissolved in water. If these solutions are not available (for instance, while traveling) the following ingredients can be stirred into one liter of bottled or boiled water: Five tablespoons of sugar One and a half level tablespoons of salt One glass of packaged orange juice In addition to drinking fluids and using other treatments , foods or dietary supplements that have probiotic microorganisms (probiotics ) in them can help to make the diarrhea go away faster. Depending on how severe the symptoms are and how long they last, other treatments may be considered too: Drugs like loperamide or racecadotril can help to slow down the activity of the bowel and lower the number of times you need to go to the bathroom. Loperamide is not suitable for children under the age of twelve years, and racecadotril is prescription-only for children. Sometimes certain types of yeast tablets (Perenterol) are also recommended. These tablets are thought to help the body get rid of the germs faster and to support natural gut flora. Charcoal tablets dissolved in water can also be taken to relieve diarrhea symptoms. But there is a lack of good-quality research in this area so no conclusions can be drawn about the benefits and harms of these treatment options. Antibiotics are only an option if the infection is bacterial. They can't fight viruses .

Drugs for Dysentery (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loperamide Approved Phase 4 53179-11-6 3955
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
4
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
5
Azithromycin Approved Phase 4 83905-01-5 55185 447043
6
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
7
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
8 Antidiarrheals Phase 4
9 Antiparasitic Agents Phase 4
10 Antimitotic Agents Phase 4
11 Citrate Phase 4
12 Anthelmintics Phase 4
13 Tubulin Modulators Phase 4
14 DMP 777 Phase 4 157341-41-8
15 Piperazine citrate Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Anti-Retroviral Agents Phase 4
18 Fluoroquinolones Phase 4
19
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
20
Zinc Approved, Investigational Phase 3 7440-66-6 32051
21 Antibiotics, Antitubercular Phase 2, Phase 3
22 Immunoglobulins Phase 3
23 Antibodies Phase 3
24 Trace Elements Phase 3
25 Nutrients Phase 3
26 Micronutrients Phase 3
27
Vancomycin Approved Phase 2 1404-90-6 441141 14969
28
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
29
Auranofin Approved, Investigational Phase 2 34031-32-8 6333901 6918453
30
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
31
Inulin Approved, Investigational, Nutraceutical Phase 1, Phase 2 9005-80-5 24763
32
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
33 Acidophilus Phase 1, Phase 2
34 Immunosuppressive Agents Phase 1, Phase 2
35 Complement System Proteins Phase 1, Phase 2
36 Complement Factor H Phase 1, Phase 2
37 Neurotransmitter Agents Phase 2
38 Histamine Antagonists Phase 2
39
Histamine Phosphate Phase 2 51-74-1 65513
40 Immunologic Factors Phase 2
41 Antacids Phase 2
42 Adjuvants, Immunologic Phase 2
43 Anti-Ulcer Agents Phase 2
44 Antirheumatic Agents Phase 2
45 rifamycin SV Phase 2
46 Rifamycins Phase 2
47 Vaccines Phase 2
48 Pharmaceutical Solutions Phase 2
49
Isoleucine Investigational, Nutraceutical Phase 2 73-32-5 6306
50
Aluminum sulfate Approved Phase 1 10043-01-3

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea Completed NCT00292344 Phase 4 Rifaximin and loperamide
2 Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases - A Phase IV Surveillance Study Completed NCT00490932 Phase 4 Hypo-osmolar ORS
3 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
4 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Recruiting NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
5 An Open Label Randomised Controlled Trial of Azithromycin Versus Ciprofloxacin for the Treatment of Children Hospitalised With Dysentery in Ho Chi Minh City, Vietnam Recruiting NCT03854929 Phase 4 Ciprofloxacin;Azithromycin
6 A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea Terminated NCT01005849 Phase 4
7 Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea Withdrawn NCT00875875 Phase 4 Rifaximin
8 Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni Completed NCT02280044 Phase 2, Phase 3
9 A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers Completed NCT01208922 Phase 3 Rifamycin SV-MMX®;Ciprofloxacin
10 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea Completed NCT01142089 Phase 3 Placebo;Rifamycin SV MMX
11 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
12 Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
13 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children Completed NCT00366730 Phase 3 Nitazoxanide
14 Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents Completed NCT00366236 Phase 3 Nitazoxanide
15 Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
16 A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea Terminated NCT02920242 Phase 3 Rifaximin (Sandoz GmbH) tablet;Rifaximin (Xifaxan);Placebo
17 Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea Withdrawn NCT02736539 Phase 3 CBS 2004 (galacto-oligosaccharides);Placebo
18 A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea Completed NCT00034294 Phase 2 GT160-246
19 Probiotics for Infectious Diarrhea in Children in South India Completed NCT01130792 Phase 1, Phase 2
20 Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults Completed NCT03527173 Phase 2 Placebo
21 Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults Completed NCT01080716 Phase 1, Phase 2
22 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults Completed NCT00751777 Phase 2
23 A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia Completed NCT01040325 Phase 2
24 Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study Completed NCT03447821 Phase 2 400 mg Rifamycin SV dosage;800 mg Rifamycin SV dosage;1200 mg Rifamycin SV dosage
25 Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity Completed NCT01034228 Phase 2
26 A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers Completed NCT00210288 Phase 2
27 A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis Completed NCT02676895 Phase 2
28 Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02646371 Phase 2
29 Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis Completed NCT00800930 Phase 2
30 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
31 Phase IIa Randomized, Single-Blinded, Placebo-Controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa Recruiting NCT02736968 Phase 2 Auranofin
32 A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries. Recruiting NCT04602975 Phase 2
33 Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants Recruiting NCT04056117 Phase 1, Phase 2
34 Phase 2b Study of the Safety, Immunogenicity, and Efficacy of a Monovalent Synthetic Carbohydrate-based Conjugate Vaccine (SF2a-TT15) for Protection Against Shigella Flexneri 2a Experimental Infection Recruiting NCT04078022 Phase 2
35 Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years Not yet recruiting NCT04026984 Phase 2 Rifamycin SV-MMX;Placebo
36 Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years Not yet recruiting NCT04027894 Phase 2 Rifamycin SV MMX;Placebo to Rifamycin SV-MMX
37 A Double-Blind Placebo Controlled Phase 2 Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of a Live-Attenuated Shigella Sonnei Vaccine, WRSs2 and Determine Its Efficacy in a Challenge Model of S. Sonnei 53G in Healthy Adults Not yet recruiting NCT04242264 Phase 2
38 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study Terminated NCT00866242 Phase 2
39 Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study Terminated NCT00866476 Phase 2
40 A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects Withdrawn NCT03038243 Phase 2
41 A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects Completed NCT01509846 Phase 1
42 A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Completed NCT03561181 Phase 1
43 A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers Completed NCT02797236 Phase 1
44 A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study Completed NCT03089879 Phase 1
45 A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity Completed NCT02445963 Phase 1
46 A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults. Completed NCT02034500 Phase 1
47 Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Completed NCT01369927 Phase 1
48 Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 Completed NCT01336699 Phase 1
49 An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects Completed NCT02089048 Phase 1 Auranofin
50 Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain Completed NCT02816346 Phase 1

Search NIH Clinical Center for Dysentery

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Ciprofloxacin
Scopolamine
Scopolamine Hydrobromide

Cochrane evidence based reviews: dysentery

Genetic Tests for Dysentery

Anatomical Context for Dysentery

MalaCards organs/tissues related to Dysentery:

40
Colon, Small Intestine, Skin, Neutrophil, Kidney, Liver, Breast

Publications for Dysentery

Articles related to Dysentery:

(show top 50) (show all 8428)
# Title Authors PMID Year
1
Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. 54 61
19028207 2008
2
Antibiotics for the empirical treatment of acute infectious diarrhea in children. 54 61
17568855 2006
3
Bioaccumulation of Organochlorine Pesticides, Procamallanus sp. (Baylis, 1923) infections, and Microbial Colonization in African Snakehead fish Sampled from Lekki Lagoon, Lagos, Nigeria. 61
33053141 2021
4
The direct and interactive impacts of hydrological factors on bacillary dysentery across different geographical regions in central China. 61
33385650 2021
5
Traditional uses, phytochemistry, pharmacology, and toxicology of Coreopsis tinctoria Nutt.: A review. 61
33309917 2021
6
Real-time forecasting and early warning of bacillary dysentery activity in four meteorological and geographic divisions in China. 61
33360132 2021
7
Effect of ambient temperatures on category C notifiable infectious diarrhea in China: An analysis of national surveillance data. 61
33198999 2021
8
Gastroprotective activity of kaempferol glycosides from Malvaviscus arboreus Cav. 61
33253829 2021
9
New lathyrane diterpenoids with anti-inflammatory activity isolated from the roots of Jatropha curcas L. 61
33301921 2021
10
Role of anthraquinones in Cassia occidentalis induced hepato-myo-encephalopathy. 61
33011371 2021
11
[Spatio-temporal dynamics of bacillary dysentery outbreaks in Democratic Republic of the Congo, 1999-2013]. 61
33518368 2021
12
Spatiotemporal variations in the incidence of bacillary dysentery and long-term effects associated with meteorological and socioeconomic factors in China from 2013 to 2017. 61
33039932 2021
13
Highly Fermentable Fiber Alters Fecal Microbiota and Mitigates Swine Dysentery Induced by Brachyspira hyodysenteriae. 61
33557345 2021
14
Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies. 61
33074530 2021
15
Contribution of noncanonical antigens to virulence and adaptive immunity in human infection with enterotoxigenic E. coli. 61
33558320 2021
16
Dysentery as the only presentation of COVID-19 in a child: a case report. 61
33557906 2021
17
Bacterial Infections in Cirrhotic Patients in a Tertiary Care Hospital. 61
33604253 2021
18
Protection against severe infectious disease in the past. 61
33573529 2021
19
Loss of the virulence plasmid by Shigella sonnei promotes its interactions with CD207 and CD209 receptors. 61
33591245 2021
20
Eukaryotic translation initiation factor 5A and its posttranslational modifications play an important role in proliferation and potentially in differentiation of the human enteric protozoan parasite Entamoeba histolytica. 61
33592076 2021
21
Detection of key sites of dimer dissociation and unfolding initiation during activation of acid-stress chaperone HdeA at low pH. 61
33253897 2021
22
Antimicrobial susceptibility of bacterial isolates from the conjunctiva, storage cases and mobile phones of university students using contact lenses. 61
31722813 2021
23
Seasonal prevalence, risk factors, and One Health intervention for prevention of intestinal parasitic infection in underprivileged communities of Thai-Myanmar border. 61
33581366 2021
24
Recent phytochemical and pharmacological advances in the genus Potentilla L. sensu lato - An update covering the period from 2009 to 2020. 61
32987127 2021
25
Dysentery as a rare GI symptom found in COVID-19 patients. 61
32711958 2021
26
Phyotochemical candidates repurposing for cancer therapy and their molecular mechanisms. 61
31883914 2021
27
A Millifluidic Perfusion Cassette for Studying the Pathogenesis of Enteric Infections Using Ex-Vivo Organoids. 61
33409849 2021
28
Comparative genome analysis of 12 Shigella sonnei strains: virulence, resistance, and their interactions. 61
32880768 2021
29
Artemisia annua - Importance in Traditional Medicine and Current State of Knowledge on the Chemistry, Biological Activity and Possible Applications. 61
33482666 2021
30
Euphorbia helioscopia L.: A phytochemical and pharmacological overview. 61
33440297 2021
31
Diagnosis of Inflammatory Bowel Disease by Abdominal ultrasound and Color Doppler Techniques. 61
33397243 2021
32
Seizure activity and anion gap metabolic acidosis secondary to adverse effect of nalidixic acid-a case report. 61
33469471 2021
33
Feiyangchangweiyan capsule protects against ulcerative colitis in mice by modulating the OSM/OSMR pathway and improving gut microbiota. 61
33113505 2021
34
Pharmacological insights into Merremia vitifolia (Burm.f.) Hallier f. leaf for its antioxidant, thrombolytic, anti-arthritic and anti-nociceptive potential. 61
33324970 2021
35
Rind from Purple Mangosteen (Garcinia mangostana) Attenuates Diet-Induced Physiological and Metabolic Changes in Obese Rats. 61
33499382 2021
36
Preformulation Characterization and the Effect of Ionic Excipients on the Stability of a Novel DB Fusion Protein. 61
32916136 2021
37
Rutaecarpine Protects against Acetaminophen-Induced Acute Liver Injury in Mice by Activating Antioxidant Enzymes. 61
33435214 2021
38
Syzygium cumini(L.),Skeels fruit extracts: In vitro and in vivo anti-inflammatory properties. 61
33465442 2021
39
Common garlic (Allium sativum L.) has potent Anti-Bacillus anthracis activity. 61
32853741 2021
40
Thalictrum minus L. ameliorates particulate matter-induced acute lung injury in mice. 61
32916235 2021
41
Heat-stable enterotoxin inhibits intestinal stem cell expansion to disrupt the intestinal integrity by downregulating the Wnt/β-catenin pathway. 61
33373490 2020
42
Gegen huangqin huanglian decoction for children rotavirus enteritis: A protocol for systematic review and meta-analysis. 61
33285720 2020
43
Lactobacillus acidophilus attenuates toxin production by Vibrio cholerae and shigella dysenteriae following intestinal epithelial cells infection. 61
33010360 2020
44
A preliminary study of bowel rest strategy in the management of Clostridioides difficile infection. 61
33328505 2020
45
Low protein diets without medicinal zinc oxide for weaned pigs reduced diarrhea treatments and average daily gain. 61
33516025 2020
46
Plagues, pandemics and epidemics in Irish history prior to COVID-19 (coronavirus): what can we learn? 61
32404230 2020
47
Traditional application and modern pharmacological research of Artemisia annua L. 61
32758647 2020
48
The Prevalence of Shiga toxin-1 in non-Shigella dysenteriae isolates collected from diarrhea samples in patients, Ahvaz, Iran. 61
33292146 2020
49
Epidemiological characteristics and trends of notifiable infectious diseases in China from 1986 to 2016. 61
33214900 2020
50
Antiprotozoal activities of Triterpenic Acids and Ester Derivatives Isolated from the Leaves of Vitellaria paradoxa. 61
33285591 2020

Variations for Dysentery

Expression for Dysentery

Search GEO for disease gene expression data for Dysentery.

Pathways for Dysentery

Pathways related to Dysentery according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 TNF STX1A IL6 IL1B IL1A IFNA2
2
Show member pathways
12.85 TNF IL6 IL1B IL1A IFNA2 CXCL8
3
Show member pathways
12.82 TNF IL6 IL1B IL1A IFNA2 CXCL8
4
Show member pathways
12.72 TNF IL6 IL1B IL1A IFNA2 CXCL8
5
Show member pathways
12.33 TNF IL6 IL1B CRP ALB
6
Show member pathways
12.32 TNF IL6 IL1B CXCL8
7
Show member pathways
12.32 TNF IL6 CXCL8 CCR6
8
Show member pathways
12.32 TNF IL6 IL1B IL1A CXCL8
9
Show member pathways
12.25 TNF IL6 IL1A CXCL8
10 12.24 TNF IL6 IL1B IFNA2 CXCL8
11
Show member pathways
12.24 TNF IL6 IL1B IL1A IFNA2 CXCL8
12 12.23 TNF IL6 IL1B IL1A IFNA2
13
Show member pathways
12.2 TNF IL1B IL1A IFNA2 H2AC18
14
Show member pathways
12.19 TNF IL6 IL1B CXCL8
15 12.09 TNF IL6 IL1B CXCL8
16 11.97 TNF IL6 IL1B IL1A CXCL8
17 11.95 IL6 IL1B IL1A CXCL8
18 11.94 TNF TF IL6 IL1B IL1A CXCL8
19 11.93 TNF IL6 IL1B CXCL8
20 11.93 TNF IL6 IL1B IL1A CXCL8
21 11.91 TNF IL6 IL1B IL1A
22 11.83 TNF IL6 IL1B IL1A CXCL8
23 11.77 TNF IL1B CCR6
24 11.77 TNF IL6 IL1B IL1A CXCL8
25 11.76 TNF IL6 IL1B IFNA2
26
Show member pathways
11.74 TNF IL6 IL1B
27 11.67 TNF IL6 CCR6
28 11.65 TNF IL6 IL1B CXCL8
29 11.6 TNF IL6 IL1B IL1A CXCL8
30 11.59 TNF IL6 IL1B CXCL8
31 11.52 IL6 IL1B IL1A
32 11.52 TNF IL6 HP
33 11.52 TNF IL6 IL1B CXCL8
34
Show member pathways
11.47 TNF STX1A IL1B
35 11.46 TNF IL6 IL1B IL1A
36 11.39 TNF IL6 IL1B
37 11.33 TNF IL6 IL1B
38 11.31 TNF IL6 IL1B
39 11.3 TNF IL6 IL1B IL1A
40
Show member pathways
11.15 TNF IL6 IL1B IL1A CXCL8
41 11.13 TNF IL6 IL1B IL1A
42 10.74 TNF IL6 CXCL8 CRP
43 10.71 TNF IL6 IL1B IL1A CXCL8
44 10.52 IL1B IL1A

GO Terms for Dysentery

Cellular components related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TTR TNF TF STX1A IL6 IL1B
2 extracellular space GO:0005615 9.44 TTR TNF TF STX2 IL6 IL1B

Biological processes related to Dysentery according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.01 TNF IL6 IL1B IL1A CXCL8 CRP
2 immune response GO:0006955 10 TNF IL6 IL1B IL1A CXCL8 CCR6
3 cellular protein metabolic process GO:0044267 9.92 TTR TF IL6 ALB
4 defense response GO:0006952 9.9 TNF IFNA2 HP CXCL8
5 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 IL1B IL1A CXCL8
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 TNF IL6 IFNA2
7 positive regulation of interleukin-8 production GO:0032757 9.79 TNF IL6 IL1B
8 positive regulation of interleukin-6 production GO:0032755 9.78 TNF IL6 IL1B IL1A
9 acute-phase response GO:0006953 9.75 IL6 HP CRP
10 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.74 TNF IL1B IL1A
11 regulation of insulin secretion GO:0050796 9.73 TNF STX1A IL6 IL1B
12 positive regulation of vascular endothelial growth factor production GO:0010575 9.69 IL6 IL1B IL1A
13 negative regulation of neurogenesis GO:0050768 9.67 TNF IL6 IL1B
14 regulation of establishment of endothelial barrier GO:1903140 9.63 TNF IL1B
15 positive regulation of glial cell proliferation GO:0060252 9.63 TNF IL6 IL1B
16 humoral immune response GO:0006959 9.62 TNF IL6 IFNA2 CCR6
17 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
18 positive regulation of immature T cell proliferation in thymus GO:0033092 9.59 IL1B IL1A
19 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
20 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IL1B
21 fever generation GO:0001660 9.55 IL1B IL1A
22 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
23 inflammatory response GO:0006954 9.5 TNF IL6 IL1B IL1A IFNA2 CXCL8
24 negative regulation of lipid storage GO:0010888 9.43 TNF IL6 CRP
25 vascular endothelial growth factor production GO:0010573 9.33 TNF IL6 IL1B
26 cytokine-mediated signaling pathway GO:0019221 9.23 TNF STX1A IL6 IL1RAPL2 IL1B IL1A

Molecular functions related to Dysentery according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 TNF IL6 IL1B IL1A IFNA2 CXCL8

Sources for Dysentery

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....